Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.

Citing topline data from its STEP-UP Phase